BillionToOne, Inc. (BLLN) Fair Value 2026

BLLN · Services-Medical Laboratories ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 13 models active

Value Trap Risk

— (—/100)

Quick Summary — As of 2026-07-15, BillionToOne, Inc. (BLLN) trades at $129.88, approximately 245% above CirclFi’s Bayesian DCF fair value of $37.62. QOC: 6.0/10. 13/13 models active.

Key Facts

Ticker
BLLN
Price
$129.88
Quality Score
6.0/10
Value Trap Risk
—/100
Models Active
13/13
Last Updated
Strength: 13 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is BillionToOne, Inc. (BLLN) Undervalued or Overvalued in 2026?

According to CirclFi’s 13-model valuation engine, BillionToOne, Inc. (BLLN) appears overvalued as of : the median of 13 independent fair value estimates is $6.92, 94.7% below the current price of $129.88. Estimates range from $0.49 to $116.81. BLLN scores 6.0/10 on fundamental quality and —/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy BillionToOne, Inc. Stock in 2026? →

Valuation Matrix

13 Intrinsic Value Models vs. Current Price ($129.88)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $37.62 -71.0%
Earnings Power Value
Low Conviction
 $3.99 -96.9%
CUCE Ensemble
Low Conviction
 $14.08 -89.2%
First Chicago
Medium Conviction
 $8.20 -93.7%

Unlock the Full Matrix

Access 9 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 13 Models →

Cancel anytime · No contracts · Instant access

What Is BillionToOne, Inc. (BLLN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, BillionToOne, Inc.'s intrinsic value is estimated at $21.70. Trading at its current price of $129.88, the valuation engine raises significant caution: 13 of 13 models flag downside risk, projecting an average implied return of -83.3%. Model dispersion is worth noting: PWERM targets $116.81 (-10.1%), versus Markov DDM at $0.49 (-99.6%). This +89.6% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About BLLN?

13 of 13 models are currently active for BLLN. All 13 active models suggest the stock trades above fair value. The Bayesian DCF estimates BLLN's intrinsic value at $37.62, implying -71.0% downside from the current price. See which stocks rank higher →

How Does BLLN Rank in Services-Medical Laboratories?

Among 24 Services-Medical Laboratories stocks, BLLN ranks #15 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.

BillionToOne, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BLLN a Value Trap?

The Value Trap algorithm is not active for BLLN. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

13 of 13 models are active for BillionToOne, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, BillionToOne, Inc. earns a quality score of 6.0/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +89.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BLLN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BLLN's 13 active models, average confidence is 19%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy BillionToOne, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Services-Medical Laboratories Stocks Should You Also Analyze?

8 related Services-Medical Laboratories stocks with 13-model coverage

CSTLCastle Biosciences, Inc.QOC 9.2VCYTVeracyte, Inc.QOC 8.8DGXQuest Diagnostics IncorporatedQOC 8.3CDNACareDx, Inc.QOC 7.8FLGTFulgent Genetics, Inc.QOC 7.7LHLabcorp Holdings Inc.QOC 7.6RDNTRadNet, Inc.QOC 7.1XGNExagen Inc.QOC 7.0

Read investment analysis: CSTL · VCYT · DGX · CDNA · FLGT

Frequently Asked Questions About BillionToOne, Inc.

What is BillionToOne, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, BillionToOne, Inc. (BLLN) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $37.62. The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BLLN overvalued or undervalued right now?

At $129.88, 0 of 13 active models suggest BLLN may be undervalued, while 13 indicate potential overvaluation. The median of all 13 fair value estimates is $6.92, 94.7% below the current price of $129.88 — a consensus view that BLLN is overvalued. The assessment depends on which methodology best fits BillionToOne, Inc.'s business model in Services-Medical Laboratories.

What does a Quality of Company score of 6.0 mean for BLLN?

BillionToOne, Inc.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on BLLN?

CirclFi analyzes BLLN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 13 of 13 are active for this stock. Read the full methodology →

Is BLLN a value trap in 2026?

CirclFi's Value Trap algorithm does not have sufficient data for BLLN at this time. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 13-model valuation engine, BillionToOne, Inc. (BLLN) has a median fair value of $6.92 — 94.7% below the current price of $129.88 — as of 2026-07-15.” Source: circlfi.com/stock/BLLN/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 13 mathematical frameworks give you clarity on BLLN.

Unlock All 13 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access